Kynurenine Aminotransferase II (human) (rec.) (His)
| Code | Size | Price |
|---|
| AG-40T-0102-C050 | 50 ug | £357.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Enzyme
Regulatory Status: RUO
Target Species: Human
Shipping:
Dry Ice
Storage:
-80°C
Documents
Further Information
Alternate Names/Synonyms:
hKAT II; KAT2; alpha-Aminoadipate Aminotransferase (Mitochondrial); AADAT; EC 2.6.1.7
Concentration:
0.5mg/ml (Lot specific)
EClass:
32160000
Endotoxin:
N/A
Form (Short):
liquid
Formulation:
Liquid. In 50 mM phosphate buffer pH 8.0, containing 50mM sodium chloride and 40µM pyridoxal 5'-phosphate (PLP).
Handling Advice:
After opening, prepare aliquots and store at -80°C.Avoid freeze/thaw cycles.
Long Description:
Protein. Human full-length KAT II is fused at the N-terminus to a His-tag. Source: E. coli. Endotoxin content: N/A. Liquid. In 50 mM phosphate buffer pH 8.0, containing 50mM sodium chloride and 40µM pyridoxal 5'-phosphate (PLP). Purity: >97% (SDS-PAGE). Kynurenine aminotransferases (KATs) are pyridoxal-5?-phosphate-dependent enzymes that catalyze the conversion of L-kynurenine into kynurenic acid, a neuroactive metabolite whose unbalancing is associated with a number of brain disorders. Biochemical and structural investigations revealed that L-kynurenine (L-KYN) recognition by hKAT II is achieved by exploiting structural features that are peculiar of this isoform, thus offering the possibility to select/design inhibitor molecules specifically targeting hKAT II to be used as modulators of kynurenic acid synthesis in the CNS. hKAT II is one of the aminotransferases involved in the pyridoxal 5'-phosphate (PLP)-dependent irreversible transamination of L-kynurenine (L-KYN) to kynurenic acid (KYNA) in the central nervous system. When assayed in vitro the protein also displays beta-elimination activity.
Molecular Weight:
~49.8kDa
NCBI, Uniprot Number:
NCBI link NP_872603
Package Type:
Plastic Vial
Product Description:
Kynurenine aminotransferases (KATs) are pyridoxal-5?-phosphate-dependent enzymes that catalyze the conversion of L-kynurenine into kynurenic acid, a neuroactive metabolite whose unbalancing is associated with a number of brain disorders. Biochemical and structural investigations revealed that L-kynurenine (L-KYN) recognition by hKAT II is achieved by exploiting structural features that are peculiar of this isoform, thus offering the possibility to select/design inhibitor molecules specifically targeting hKAT II to be used as modulators of kynurenic acid synthesis in the CNS. hKAT II is one of the aminotransferases involved in the pyridoxal 5'-phosphate (PLP)-dependent irreversible transamination of L-kynurenine (L-KYN) to kynurenic acid (KYNA) in the central nervous system. When assayed in vitro the protein also displays beta-elimination activity.
Purity:
>97% (SDS-PAGE)
Sequence:
Human full-length KAT II is fused at the N-terminus to a His-tag.
Source / Host:
E. coli
TAGs:
His
Transportation:
Non-hazardous
UNSPSC Category:
Other Enzymes
UNSPSC Number:
12352204
Use & Stability:
Stable for at least 6 months after receipt when stored at -80°C.
References
Crystal Structure of Human Kynurenine Aminotransferase II, a Drug Target for the Treatment of Schizophrenia; F. Rossi, et al.; J. Biol. Chem. 283, 3559 (2008) | Biochemical and Structural Investigations on Kynurenine Aminotransferase II: An Example of Conformation-Driven Species-Specific Inhibition?; V. Casazza, et al.; Curr. Top. Med. Chem. 11, 148 (2011) | Human kynurenine aminotransferase II - reactivity with substrates and inhibitors; E. Passera, et al.; FEBS J. 278, 1882 (2011) | A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growth: T. Yoshida, et al.; BBRC 522, 633 (2019)